# Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia

> **NCT01460693** · PHASE3 · COMPLETED · sponsor: **Newcastle University** · enrollment: 814 (actual)

## Conditions studied

- Myeloid Leukemia, Chronic, Chronic Phase

## Interventions

- **DRUG:** Imatinib
- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT01460693
- **Lead sponsor:** Newcastle University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2018-03-07
- **Final completion:** 2018-03-07
- **Target enrollment:** 814 (ACTUAL)
- **Last updated:** 2018-04-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01460693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01460693, "Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01460693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*